Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 206

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 206
---
U 2023-09,
"Income Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income
tax disclosures. This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional
information for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose
the amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the
standard. The adoption of this standard is not expected to have a material impact on our financial statements.

| 4. | Intangible Assets |

The Company’s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.

The following is a summary of the Company’s intangible assets:

| Schedule of intangible assets  |     |   | March 31, 2025 |   |     |   | June 30, 2024 |   |
|:-------------------------------|:----|:--|---------------:|:--|:----|:--|--------------:|:--|
| Intellectual Property          |     | $ |      2,293,770 |   |     | $ |     2,293,770 |   |
| Less: Accumulated Amortization |     |   |     (2,058,085 | ) |     |   |    (1,886,052 | ) |
| Intellectual Property, Net     |     | $ |        235,685 |   |     | $ |       407,718 |   |

Amortization expense was $57,344 in each of the three-month
periods ended March 31, 2025 and 2024. Amortization expense was $172,033 in each of the nine-month periods ended March 31, 2025 and 2024.
The Company amortizes intellectual property over the expected original useful lives of 10 years.

Estimated future amortization expense is as follows:

| Schedule of future amortization expense        |     |   |         |